**Mitchell Jones** is a Former Vice President, [[Translational Science|Translational and Clinical Development]] for [[Biora Therapeutics|Biora Therapeutics]]. Former Founder, Head of Research, CSO of [[Interface Therapeutics Inc.]]. Former Founder, Head of Research, CSO of [[Micropharma]]. Currently Vice President, Clinical Discovery and Development for [[Finch Therapeutics]]. > [!info] Finch Therapeutics - Mitch Jones > Dr. Jones joins Finch with more than 14 years of experience in discovery and clinical development of novel therapeutics. Most recently, Dr. Jones provided leadership for translational and clinical development within the Precision Medicine group at Progenity, developing novel oral biotherapeutics and modified release oral combination products to treat metabolic disease and disorders of the gastrointestinal tract. Prior to that, Dr. Jones founded and served as the CMO of Interface, acquired by Progenity, where he was responsible for developing a novel platform sampling technology and multi-omics approach to develop therapeutics acting at the host-microbiome interface. Prior to that, Dr. Jones founded and served as the CSO of Micropharma, acquired by UAS Labs followed by Chr Hansen, where he was responsible for discovery and clinical development of microbiome-based therapeutics for metabolic and inflammatory disease. Dr. Jones has authored over 60 peer-reviewed publications and abstracts and has been an inventor on over 70 patent families and 190 individual applications. He has initiated and directed numerous therapeutic clinical studies in the human-microbiome space, as well as other studies involving orally-delivered combination products. > > Dr. Jones received his PhD in Biomedical Engineering, with a focus on developing human-microbiome therapeutics, as well as his MD from McGill University in Quebec, Canada. > > Source: [Finch Therapeutics | About](https://www.finchtherapeutics.com/about/)